Stock Taper 
Foghorn Therapeutics Inc. is a Cambridge-based biotech developing targeted cancer therapies using its Gene Traffic Control platform, with programs against BRG1, BRM, BRD9, and ARID1B, and collaborations with Merck and Loxo Oncology.
A first-in-class oral small molecule inhibiting SMARCA2, in Phase 1 trials for SMARCA4-mutant cancers like NSCLC, developed with Eli Lilly.
On November 5, 2025, Foghorn Therapeutics reported third-quarter earnings that surpassed analyst expectations for both earnings per share and revenue. Simultaneously, the company announced the planned departure of its Chief Financial Officer, Kristian Humer, a move that was presented alongside a strong financial position, including a cash runway extending into 2028, which appeared to mitigate potential investor concerns.
In early 2025, Foghorn Therapeutics publicly outlined its strategic objectives for the year, centering on the advancement of its clinical and preclinical programs. This included progressing the Phase 1 trial of its oral selective SMARCA2 inhibitor, FHD-909, and advancing its selective degrader programs for ARID1B, CBP, and EP300.
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock is trading lower on Thursday with a session volume of 9.158 million, compared to the average volume of 377.206 thousand, as per Benzinga Pro data.
Foghorn Therapeutics and Eli Lilly don't plan any future collaborations following the dissolution of a cancer-drug partnership.
Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program Company to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and induced proximity platform Pipeline prioritization and organizational changes expected to extend cash runway into the second half of 2029, including an approximately 40% workforce reduction WATERTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines that treat serious diseases, today announced that, following a review of clinical data from the Phase 1 dose escalation trial of FHD-909 (LY4050784), Foghorn and Lilly have decided not to advance the program into the clinical development expansion phase.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 ASMB | $22.70 | COMPARE |
 ZURA | $3.97 | COMPARE |
 ARCT | $12.80 | COMPARE |
 ENTA | $12.23 | COMPARE |
 SGMT | $8.84 | COMPARE |
 VNDA | $4.50 | COMPARE |
 TRDA | $5.46 | COMPARE |
 IMRX | $3.69 | COMPARE |
